Analysis of Urinary, Vaginal & Intestinal Microbiota in Patients With

Status Not yet recruiting

Clinical Trial Summary

The neurogenic bladder and bowel are two pathological conditions occurring when damaged innervation results in functional alteration of both the bladder and the bowel with a clinical presentation that can vary from retention to incontinence often associated with an increased risk of infection. Specific microbiological patterns of urinary microbiota are associated with states of well-being of the host and play protective and preventive functions for numerous urological pathologies such as urinary tract infections, urinary incontinence and bladder tumors. What the "healthy" profile of the bladder microbiota is in subjects with neurogenic bladder appears currently poorly reported in literature data. Indeed, in these populations different strains of uropathogenic microorganisms, such as E.Coli, Klebsiella, Pseudomonas and Enterococcus, are dominant compared to healthy subjects where Lactobacillus predominates. The characterization of the gut microbiota in terms of composition can be a key tool for understanding the effects that preventive therapeutic and nutritional approaches or clinical procedures have on it, subsequently offering the possibility of improving and complementing these treatments. Among human microbiota, the vaginal one, the "vaginoma", is among the most studied for its correlation with female health status. The "core" of the vaginal microbiome is Lactobacillus which under physiological conditions is represented in particular by Lactobacillus Crispatus, Lactobacillus Iners, Lactobacillus Jensenii and Lactobacillus Gasseri. Immune cells and related PRRs receptors interact with the microorganisms in the vaginal environment of the vaginal environment are the immune cells and the related PRRs receptors thus the close relationship between microbiome and immunity as well as between vaginoma and genitourinary well-being is now evident. The characterization of the gut, urinary and vaginal microbiota in patients with neurogenic bladder secondary to spina bifida and multiple sclerosis can help identify a "health promoting" profile to personalize and characterize the therapeutic approach.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06093035
Study type	Observational [Patient Registry]
Source	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact
Status	Not yet recruiting
Phase
Start date	November 10, 2023
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05414994` - Assessment of the Ocular Microbiome in Health and Disease
Completed	`NCT04769882` - Er:YAG Laser Effects on Microbial Population in Conservative Dentistry	N/A
Completed	`NCT04766528` - Effect of Diet on the Microbiota / Endoccanabinoidome Axis in Response to Physical Activity	N/A
Completed	`NCT03720314` - Microbiota Profiling in IBS
Completed	`NCT04122612` - Shaping Microbiome in the First 1,000 Days of Life
Not yet recruiting	`NCT05405634` - Microbiota in Chronic Anal Fissure and Its Association With Prognosis
Not yet recruiting	`NCT04895774` - Ex Vivo Study of the Mechanism of Action of Active Ingredients on the Intestinal Microbiota
Recruiting	`NCT05992688` - The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)	N/A
Recruiting	`NCT05502380` - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery	Phase 3
Completed	`NCT05175833` - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19	Phase 2
Recruiting	`NCT04836910` - Microbiome and Polycystic Ovaries
Recruiting	`NCT05603650` - Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract	N/A
Completed	`NCT05575050` - Impact of Teeth Brushing in Ventilated COVID-19 Patients.	N/A
Completed	`NCT04991818` - MSC - OneBiome UX Pilot Study	N/A
Completed	`NCT04374955` - The Effect of Probiotic Added to Maternal Diet on Infantile Colic and Intestinal Microbiota Content	N/A
Recruiting	`NCT04140747` - Transfer of Strictly Anaerobe Microbes From Mother to Child
Recruiting	`NCT04111471` - The Use of A Prebiotic to Promote a Healthy Gut Microbiome in Pediatric Stem Cell Transplant Recipients	N/A
Suspended	`NCT03220282` - The Milk, Growth and Microbiota Study	N/A
Completed	`NCT03422562` - Probiotics and Intestinal Microbiome in Preterm Infants	Phase 3
Recruiting	`NCT05695196` - Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Analysis of Urinary, Vaginal and Intestinal Microbiota in Patients With Neurogenic Bladder

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms